Merck Animal Health is pleased to announce that Harrisvaccines, which was acquired by the company in November, received the Technology Association of Iowa (TIA) 2016 Prometheus Awards for Best User of Technology, Life Sciences Company of the Year and Small/Medium Technology Company of the Year.
“This recognition from the TIA distinguishes the team’s pioneering spirit and commitment to the advancement of our technology and product offerings,” said Shannon Kellner, Associate Vice President, Merck Animal Health. “As a leader in biologics, we have built a robust portfolio of vaccines across all animal species. Combine those products with our newly acquired technologies, and our strong capabilities and global reach, and we are well positioned to meet the continually evolving health needs of our customers and reinforce our commitment to the science of healthier animals.”
In addition, Mark Mogler, Ph.D., Principal Scientist, Biology-Discovery, was named "Chief Scientific Officer of the Year”, honored for his role in developing Harrisvaccines’ most impactful product in 2015 – Avian Influenza Vaccine, RNA. Highly Pathogenic Avian Influenza (HPAI) killed more than 50 million chickens and turkeys in the United States last year. This vaccine could be instrumental in minimizing the impact of similar outbreaks in the future.
“I am incredibly honored to be recognized by the TIA,” said Dr. Mogler. “My role in the development of the HPAI vaccine was a significant career milestone, and I look forward to continuing to identify innovative vaccine technologies that will help protect animals’ health and improve customers’ bottom lines. I take great pride in the work our team does to deliver meaningful solutions.”
The Prometheus Awards are Iowa’s largest and most prestigious honor, recognizing and celebrating the innovation and brilliance of Iowa’s high-tech industry, as well as companies and individuals who have demonstrated outstanding leadership and excellence in technology.
Source : Merck